[1]
|
M. E. Kadin and S. W. Morris, “The t(2;5) in Human Lymphomas,” Leukemia & Lymphoma, Vol. 29, No. 3-4, 1998, pp. 249-256. doi:10.3109/10428199809068562
|
[2]
|
H. Stein, D. Y. Mason, J. Gerdes, et al., “The Expression of the Hodgkin’s Diseaseassociated Antigen Ki-1 in Reactive and Neoplastic Lymphoid Tissue: Evidence That Reed-Sternberg Cells and Histiocytic Malignancies Are Derived from Activated Lymphoid Cells,” Blood, Vol. 66, No. 4, 1985, pp. 848-858.
|
[3]
|
N. L. Harris, E. S. Jaffe, H. Stein, et al., “A Revised European-American Classification of Lymphoid Neoplasms: A Proposal from the International Lymphoma Study Group,” Blood, Vol. 84, No. 5, 1994, pp. 1361-1392.
|
[4]
|
S. H. Swerdlow, E. Campo, N. L. Harris, E. S. Jaffe, S. A. Pileri, H. Stein, J. Thiele and J. W. Vardiman, “WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues,” IARC, Lyon, 2008.
|
[5]
|
K. J. Savage, N. L. Harris, J. M. Vose, et al., “ALK-Negative Anaplastic Large-Cell Lymphoma (ALCL) Is Clinically and Immunophenotypically Different from Both ALKPositive ALCL and Peripheral T-Cell Lymphoma, Not Otherwise Specified: Report from the International Peripheral T-Cell Lymphoma Project,” Blood, Vol. 111, No. 12, 2008, pp. 5496-5504.
doi:10.1182/blood-2008-01-134270
|
[6]
|
F.-H. Wang, Y.-H. Li, J. Zeng, H.-L. Rao, Z.-J. Xia, X.-F. Sun, H.-Q. Huang, T.-Y. Lin, W.-Q. Jiang and Z.-Z. Guan, “Clinical Analysis of Primary Systemic Anaplastic Large Cell Lymphoma: A Report of 57 Cases,” Chinese Journal of Cancer, Vol. 28, No. 1, 2009.
|
[7]
|
D. A. Filippa, M. Ladanyi, N. Wollner, et al., “CD30 (Ki-1)-Positive Malignantlymphomas: Clinical, Immunophenotypic, Histologic, and Genetic Characteristics and Differences with Hodgkin’s Disease,” Blood, Vol. 87, No. 7, 1996, pp. 2905-2917.
|
[8]
|
B. Falini, S. Pileri, P. L. Zinzani, et al., “ALK + Lymphoma: Clinico-Pathological Findings and Outcome,” Blood, Vol. 93, No. 8, 1999, pp. 2697-2706.
|
[9]
|
M. E. Kadin and C. Carpenter, “Systemic and Primary Cutaneous Anaplasticlarge Cell Lymphomas,” Seminars in Hematology, Vol. 40, No. 3, 2003, pp. 244-256.
doi:10.1016/S0037-1963(03)00138-0
|
[10]
|
J. T. Sandlund, C. H. Pui, V. M. Santana, et al., “Clinical Features and Treatment Outcome for Children with CD30+ Large-Cell Non-Hodgkin’s Lymphoma,” Journal of Clinical Oncology, Vol. 12, No. 5, 1994, pp. 895-898.
|
[11]
|
M. Herling, G. Z. Rassidakis, D. Jones, et al., “Absence of Epstein-Barr Virus Inanaplastic Large Cell Lymphoma: A Study of 64 Cases Classified According to World Health Organization Criteria,” Human Pathology, Vol. 35, No. 4, 2004, pp. 455-459.
doi:10.1016/j.humpath.2003.10.013
|
[12]
|
S. Noorali, S. Pervez, N. Yaqoob, et al., “Prevalence and Characterization of Anaplastic Large Cell Lymphoma and Its Association with Epstein-Barrvirus in Pakistani Patients,” Pathology—Research and Practice, Vol. 200, No. 10, 2004, pp. 669-679. doi:10.1016/j.prp.2004.08.004
|
[13]
|
V. Costes-Martineau, C. Delfour, S. Obled, et al., “Anaplastic Lymphomakinase (ALK) Protein Expressing Lymphoma after Liver Transplantation: Case Report and Literature Review,” Journal of Clinical Pathology, Vol. 55, No. 11, 2002, pp. 868-871. doi:10.1136/jcp.55.11.868
|
[14]
|
R. D. Gascoyne, L. Lamant, J. I. Martin-Subero, et al., “ALK-Positive Diffuse Large B-Cell Lymphoma Is Associated with Clathrin-ALK Rearrangements: Report of 6 Cases,” Blood, Vol. 102, No. 7, 2003, pp. 2568-2573.
doi:10.1182/blood-2003-03-0786
|
[15]
|
H. Ruchatz, A. M. Coluccia, P. Stano, et al., “Constitutive Activation of Jak2 Contributes to Proliferation and Resistance to Apoptosis in NPM/ALK Transformed Cells,” Experimental Hematology, Vol. 31, No. 4, 2003, pp. 309-315. doi:10.1016/S0301-472X(03)00007-9
|
[16]
|
R. L. Ten Berge, J. J. Oudejans, G. J. Ossenkoppele, et al., “ALK Expression in Extranodal Anaplastic Large Cell Lymphoma Favours Systemic Diseasewith (Primary) Nodal Involvement and a Good Prognosis and Occurs before Dissemination,” Journal of Clinical Pathology, Vol. 53, No. 6, 2000, pp. 445-450. doi:10.1136/jcp.53.6.445
|
[17]
|
R. D. Gascoyne, P. Aoun, D. Wu, et al., “Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults with Anaplasticlarge Cell Lymphoma,” Blood, Vol. 93, 1999, pp. 3913-3921.
|
[18]
|
L. Lamant, A. de Reyniès, M. M. Duplantier, et al., “GeneExpression Profiling of Systemic Anaplastic Large-Cell Lymphoma Reveals Differences Based on ALK Status and Two Distinct Morphologic ALK+ Subtypes,” Blood, Vol. 109, No. 5, 2007, pp. 2156-2164.
doi:10.1182/blood-2006-06-028969
|
[19]
|
M. Shiota, S. Nakamura, R. Ichinohasama, et al., “Anaplastic Large Cell Lymphomas Expressing the Novel Chimeric Protein p80NPM/ALK: A Distinct Clinic Opathologic Entity,” Blood, Vol. 86, No. 5, 1995, pp. 1954-1960.
|
[20]
|
K. J. Savage, N. L. Harris, J. M. Vose, et al., “ALK-Negative Anaplastic Large-Cell Lymphoma (ALCL) Is Clinically and Immunophenotypically Different from Both ALK-Positive ALCL and Peripheral T-Cell Lymphoma, Not Otherwise Specified: Report from the International Peripheral T-Cell Lymphoma Project,” Blood, Vol. 111, No. 12, 2008, pp. 5496-5504.
doi:10.1182/blood-2008-01-134270
|
[21]
|
P. L. Zinzani, M. Martelli, M. Magagnoli, et al., “Anaplastic Large Cell Lymphoma Hodgkin’s-Like: A Randomized Trial of ABVD versus Macop-B with and without Radiation Therapy,” Blood, Vol. 92, No. 3, 1998, pp. 790-794.
|
[22]
|
H. Tilly, P. Gaulard, E. Lepage, et al., “Primary Anaplastic Large-Cell Lymphomain Adults: Clinical Presentation, Immunophenotype, and Outcome,” Blood, Vol. 90, No. 9, 1997, pp. 3727-3734.
|
[23]
|
R. I. Fisher, E. R. Gaynor, S. Dahlberg, et al., “Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin’s Lymphoma,” The New England Journal of Medicine, Vol. 328, No. 14, 1993, pp. 1002-1006.
doi:10.1056/NEJM199304083281404
|
[24]
|
K. Seidemann, M. Tiemann, M. Schrappe, et al., “ShortPulse B-Non-Hodgkin Lymphoma-Type Chemotherapy Is Efficacious Treatment for Pediatric Anaplastic Large Cell Lymphoma: A Report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90,” Blood, Vol. 97, No. 12, 2001, pp. 3699-3706. doi:10.1182/blood.V97.12.3699
|
[25]
|
S. R. Park, J. Y. Baek, D. W. Kim, et al., “Primary Systemic Anaplastic Large Cell Lymphoma in a Single Korean Institution: Clinical Characteristics and Treatment Outcome,” Journal of Korean Medical Science, Vol. 21, No. 4, 2006, pp. 633-638.
doi:10.3346/jkms.2006.21.4.633
|
[26]
|
T. Mori, T. Takimoto, N. Katano, et al., “Recurrent Childhood Anaplastic Large Cell Lymphoma: A Retrospective Analysis of Registered Cases in Japan,” British Journal of Haematology, Vol. 132, No. 5, 2006, pp. 594-597.
doi:10.1111/j.1365-2141.2005.05910.x
|
[27]
|
Jagasia, M., Morgan, D., Goodman, S., et al. (2004) Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leukemia & Lymphoma, 45, 2261-2267
|